Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bacteriocin production by group a streptococcal L-forms

W Hryniewicz, J R Tagg

    Antimicrobial Agents and Chemotherapy
    |December 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Postbiotics: what are they?

    Beneficial microbes·2025
    Same author

    Country-wide expansion of a VIM-1 carbapenemase-producing Klebsiella oxytoca ST145 lineage in Poland, 2009-2019.

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2023
    Same author

    MDR carbapenemase-producing Klebsiella pneumoniae of the hypervirulence-associated ST23 clone in Poland, 2009-19.

    The Journal of antimicrobial chemotherapy·2022
    Same author

    Safety assessment of <i>Streptococcus salivarius</i> M18 a probiotic for oral health.

    Beneficial microbes·2022
    Same author

    Molecular and genomic epidemiology of VIM/IMP-like metallo-β-lactamase-producing Pseudomonas aeruginosa genotypes in Poland.

    The Journal of antimicrobial chemotherapy·2021
    Same author

    Spread of Klebsiella pneumoniae ST45 Producing GES-5 Carbapenemase or GES-1 Extended-Spectrum β-Lactamase in Newborns and Infants.

    Antimicrobial agents and chemotherapy·2020

    Group A Streptococcus L-forms retain streptococcin production and immunity. However, L-forms from cured strains lose this ability and become susceptible to the bacteriocin.

    Area of Science:

    • Microbiology
    • Bacteriology
    • Streptococcal Infections

    Background:

    • Group A Streptococcus (GAS) is a significant human pathogen.
    • Bacteriocins, such as streptococcin, are antimicrobial peptides produced by bacteria.
    • Bacterial L-forms are cells that have lost their cell walls, altering their characteristics.

    Purpose of the Study:

    • To investigate the characteristics of L-forms derived from a bacteriocin-producing strain of Group A Streptococcus.
    • To determine if L-forms retain the ability to produce bacteriocins and exhibit immunity.
    • To compare L-forms from producing and non-producing strains.

    Main Methods:

    • Induction of L-forms from a bacteriocin-producing Group A Streptococcus strain.
    • Induction of L-forms from a spontaneously cured (bacteriocin-negative) derivative strain.

    Related Experiment Videos

  • Assaying L-forms for streptococcin production.
  • Testing L-form sensitivity to homologous bacteriocin.

    • Main Results:

    • L-forms derived from the bacteriocin-producing GAS strain maintained the capacity for streptococcin production.
    • These L-forms also retained immunity to the streptococcin produced by the parent strain.
    • L-forms generated from a cured, bacteriocin-negative GAS strain did not produce streptococcin.
    • The L-forms from the cured strain were sensitive to the action of streptococcin.

    Conclusions:

    • Cell wall deficient L-forms of Group A Streptococcus can retain bacteriocinogenic potential and self-immunity.
    • Loss of bacteriocin production in the parent strain leads to a similar loss in its derived L-forms.
    • These findings shed light on the stability of bacteriocin production and immunity in altered bacterial forms.